Maze Therapeutics (MAZE) Completes Phase 2 HORIZON Enrollment For MZE829Simplywall·Nov 11, 2026 at 05:56 PMMAZE+3.61%
JP Morgan maintains Maze Therapeutics at Overweight, lowers price target to $51 from $53TradingView·Nov 11, 2026 at 04:30 PMMAZE+3.61%
Maze Therapeutics: Buy Rating Maintained with $110 Price Target Unchanged on MZE829’s Strong PotentialTip Ranks·Nov 10, 2026 at 08:25 PMMAZE+3.61%
Maze Therapeutics presents MZE829 data showing 36% mean reduction in proteinuria in evaluable AMKD patientsPUBT·Nov 9, 2026 at 09:30 PMMAZE+3.61%
Is Maze Therapeutics (MAZE) Fully Priced After Its 24% Jump?Simplywall·Nov 6, 2026 at 12:32 PMMAZE+3.61%
Maze Therapeutics CEO Jason V Coloma Reports Disposal of $1.04 Million in Common SharesPUBT·Nov 4, 2026 at 09:17 PMMAZE+3.61%
Maze Therapeutics CEO to Participate in Three Investor ConferencesPUBT·Nov 3, 2026 at 12:11 PMMAZE+3.61%
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $240,525.00 in StockMarket Beat·Oct 30, 2026 at 09:08 PMMAZE+3.61%
Maze Therapeutics CSBO Atul Dandekar Reports Sale of Common Shares Worth $240,531.75PUBT·Oct 30, 2026 at 08:15 PMMAZE+3.61%
Canaccord Genuity Group Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE)Market Beat·Oct 20, 2026 at 12:00 PMMAZE+3.61%
Maze Therapeutics shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $75 price target.benzinga_article·Oct 19, 2026 at 04:29 PMMAZE+3.61%
